Your browser is no longer supported. Please, upgrade your browser.
Aptinyx Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own1.80% Shs Outstand67.72M Perf Week-11.16%
Market Cap146.89M Forward P/E- EPS next Y-1.13 Insider Trans6.96% Shs Float60.13M Perf Month-12.96%
Income-66.80M PEG- EPS next Q-0.26 Inst Own55.50% Short Float0.78% Perf Quarter-18.25%
Sales1.00M P/S146.89 EPS this Y40.10% Inst Trans-3.01% Short Ratio2.93 Perf Half Y-19.78%
Book/sh1.65 P/B1.30 EPS next Y6.00% ROA-46.80% Target Price9.33 Perf Year-44.01%
Cash/sh1.83 P/C1.17 EPS next 5Y- ROE-49.70% 52W Range2.10 - 4.73 Perf YTD-37.86%
Dividend- P/FCF- EPS past 5Y- ROI-34.80% 52W High-54.55% Beta1.32
Dividend %- Quick Ratio21.10 Sales past 5Y- Gross Margin- 52W Low2.38% ATR0.14
Employees34 Current Ratio21.10 Sales Q/Q- Oper. Margin- RSI (14)41.73 Volatility8.02% 5.86%
OptionableYes Debt/Eq0.12 EPS Q/Q-29.90% Profit Margin- Rel Volume1.08 Prev Close2.28
ShortableYes LT Debt/Eq0.12 EarningsNov 09 AMC Payout- Avg Volume159.74K Price2.15
Recom1.70 SMA20-8.24% SMA50-7.06% SMA200-19.94% Volume172,947 Change-5.70%
Oct-27-20Initiated Piper Sandler Overweight $10
Jul-01-20Initiated SunTrust Buy $15
May-08-20Initiated William Blair Outperform
Apr-29-20Initiated H.C. Wainwright Buy $7
Sep-12-19Initiated Wedbush Outperform
Aug-13-19Downgrade JP Morgan Neutral → Underweight
Jun-20-19Initiated SVB Leerink Outperform $12
Jan-17-19Downgrade JP Morgan Overweight → Neutral
Nov-15-18Initiated Cantor Fitzgerald Overweight $40
Jul-16-18Initiated Leerink Partners Outperform $35
Jul-16-18Initiated JP Morgan Overweight $30
Nov-18-21 07:49AM  
Nov-16-21 12:43PM  
Nov-10-21 07:32AM  
Nov-09-21 04:05PM  
Oct-27-21 06:47AM  
Oct-25-21 07:32AM  
Oct-20-21 07:57AM  
Sep-20-21 07:57AM  
Sep-16-21 06:37AM  
Aug-31-21 07:57AM  
Aug-11-21 03:01AM  
Aug-10-21 05:49PM  
Aug-03-21 07:57AM  
Jul-29-21 01:25AM  
Jul-26-21 07:57AM  
Jul-12-21 07:57AM  
Jul-06-21 07:57AM  
Jun-17-21 07:57AM  
Jun-16-21 06:45AM  
Jun-15-21 04:10PM  
Jun-10-21 11:35AM  
May-14-21 04:00AM  
May-13-21 04:05PM  
May-10-21 07:57AM  
Apr-29-21 04:05PM  
Apr-27-21 07:57AM  
Apr-06-21 06:37AM  
Mar-31-21 01:50AM  
Mar-25-21 12:00AM  
Mar-24-21 05:45PM  
Mar-17-21 12:30PM  
Mar-02-21 08:31AM  
Feb-22-21 08:30AM  
Feb-11-21 08:30AM  
Feb-10-21 05:28PM  
Feb-08-21 03:19PM  
Jan-30-21 01:19AM  
Jan-29-21 10:31AM  
Jan-19-21 08:31AM  
Jan-05-21 08:37AM  
Jan-04-21 07:57AM  
Dec-21-20 08:30AM  
Dec-16-20 08:30AM  
Dec-07-20 03:25PM  
Nov-25-20 11:40PM  
Nov-12-20 04:03PM  
Nov-10-20 08:37AM  
Oct-29-20 08:37AM  
Oct-27-20 01:35PM  
Oct-26-20 04:01PM  
Oct-21-20 10:59PM  
Oct-20-20 04:01PM  
Oct-19-20 04:44PM  
Oct-06-20 07:25AM  
Sep-28-20 08:27AM  
Sep-03-20 08:37AM  
Aug-21-20 09:33AM  
Aug-13-20 05:25PM  
Aug-06-20 12:30PM  
Aug-04-20 08:37AM  
Jul-30-20 04:01PM  
Jul-08-20 08:37AM  
Jul-07-20 12:51PM  
Jul-05-20 10:27PM  
Jun-26-20 08:37AM  
Jun-18-20 07:57AM  
Jun-16-20 08:37AM  
May-25-20 11:30AM  
May-20-20 12:00PM  
May-18-20 08:19AM  
May-16-20 08:44AM  
May-14-20 05:15PM  
May-07-20 12:30PM  
May-06-20 11:23AM  
May-04-20 12:24PM  
Apr-30-20 08:47AM  
Apr-28-20 09:00AM  
Apr-16-20 12:08PM  
Apr-03-20 12:00PM  
Apr-01-20 02:04PM  
Mar-30-20 05:45PM  
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc; and with Rosalind Franklin University of Medicine and Science. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HOMBACH ROBERT J.DirectorNov 12Buy2.4074,600179,040219,100Nov 15 06:37 PM
HOMBACH ROBERT J.DirectorNov 11Buy2.405,40012,960144,500Nov 15 06:37 PM
KIDD ANDREWPRESIDENT & COOMay 17Option Exercise0.00130,0000139,133May 19 06:48 PM
KHANNA ASHISHCFO AND CBOMay 17Option Exercise0.00130,0000413,130May 19 06:47 PM
RIEDEL NORBERT GCEOMay 17Option Exercise0.00380,0000742,539May 19 06:46 PM